Elder Pharmaceuticals

Elder Pharmaceuticals Ltd was an Indian pharmaceutical company headquartered in Mumbai, Maharashtra. Established in 1989 by Jagdish Saxena, the company grew from a small domestic manufacturing operation into a pharmaceutical business involved in the production and marketing of prescription pharmaceutical brands, surgical products, medical devices, and consumer-health offerings. Its manufacturing portfolio covered tablets, capsules, syrups, injectables, topical creams, and ointments. The company’s first manufacturing plant was established at Nerul in 1989. Over time, Elder developed a wider manufacturing footprint, with six plants in India and one in Nepal. Its business model combined in-house production with the promotion and distribution of branded formulations. The company also explored adjacent healthcare categories, including nutritional supplements, nicotine-replacement products, skin-care products, active pharmaceutical ingredients, and products aimed at rural markets. Elder became a publicly traded company in 2000, when its shares were listed on the Bombay Stock Exchange and the National Stock Exchange of India. Its international expansion included the 2010 acquisition of NeutraHealth, a supplements company based in the United Kingdom, for £12.2 million. The transaction was intended to strengthen Elder’s position in the supplements and consumer-health segment. The company later encountered severe financial and governance difficulties. In December 2013, Torrent Pharmaceuticals agreed to acquire Elder’s branded domestic formulations business in India and Nepal for ₹2,000 crore. The transaction transferred an important part of Elder’s operating business, but did not eliminate its debt burden. Elder subsequently faced continuing financial stress and was delisted from the Indian stock exchanges in 2016 because of non-compliance. The company entered liquidation in 2017. Leadership changes accompanied this decline. Founder Jagdish Saxena died in 2013, and managing director Alok Saxena died in 2017. The promoter family was subsequently associated with Jagdish Saxena’s son Anuj Saxena and daughter Shalini Saxena Kumar. Publicly documented information about Elder’s operations after liquidation is limited. A Mumbai court reportedly fined the company ₹18.3 million in 2025 for failing to honor a cheque, indicating that legal and financial matters connected with the company continued after its operating decline.

Elder Pharmaceuticals was founded in Mumbai in 1989 by Jagdish Saxena. Saxena established the business after losing his job when the pharmaceutical division of his former employer was shut down. The company’s first manufacturing plant was set up at Nerul during the same year. From this initial base, Elder developed a domestic pharmaceutical operation focused on manufacturing and marketing branded prescription medicines. The company’s manufacturing capabilities expanded across a range of dosage forms, including tablets, capsules, syrups, injectables, creams, and ointments. It also manufactured or marketed surgical and medical devices. At its larger operating scale, Elder was associated with six manufacturing plants in India and one in Nepal. Its portfolio extended beyond conventional prescription medicines into supplements, nicotine-replacement products, skin care, active pharmaceutical ingredients, and initiatives directed at rural distribution. Elder became listed on the Bombay Stock Exchange and the National Stock Exchange in 2000. The public listing provided the company with access to Indian capital markets during a period in which it was expanding its manufacturing and branded-formulations activities. It subsequently pursued international and adjacent-category growth. In 2010, Elder acquired the United Kingdom-based supplements company NeutraHealth for £12.2 million, broadening its exposure to consumer health and nutritional products. The company’s financial position deteriorated in the early 2010s. In December 2013, Torrent Pharmaceuticals signed a definitive agreement to acquire Elder’s branded domestic formulations business in India and Nepal for ₹2,000 crore. Although the transaction transferred a significant operating segment to Torrent, Elder continued to face debt-related pressure. The company’s founder, Jagdish Saxena, died in October 2013. His death occurred during a period of major transition for the business. Elder’s difficulties continued after the divestment. In 2016, it was delisted from the Indian stock exchanges because of non-compliance. Managing director Alok Saxena died in October 2017 at the age of 52. The promoter group was later associated with Jagdish Saxena’s second son, Anuj Saxena, and his daughter, Shalini Saxena Kumar. During 2017, Elder Pharmaceuticals went into liquidation, marking the end of its life as a functioning publicly traded pharmaceutical company. The company’s post-liquidation corporate and legal affairs remained relevant in later years. A Mumbai court reportedly fined Elder Pharmaceuticals ₹18.3 million in 2025 for failing to honor a cheque. Publicly available information does not establish a continuing operating business, current product sales, or an active corporate structure after liquidation. Elder is therefore best understood as a defunct Indian pharmaceutical company whose principal historical activities covered branded medicines, manufacturing, medical devices, supplements, and related healthcare products.

• 2017

  Liquidation

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Elder Pharmaceuticals entered liquidation after continuing financial difficulties.

• 2016

  Delisting

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Elder was delisted from the Bombay Stock Exchange and National Stock Exchange because of non-compliance.

• 2013

  Sale of Indian and Nepalese branded formulations business

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Torrent Pharmaceuticals agreed to acquire Elder’s branded domestic formulations business in India and Nepal for ₹2,000 crore.

• 2010

  Acquisition of NeutraHealth

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Elder acquired the United Kingdom-based supplements company NeutraHealth for £12.2 million.

• 2000

  Listing on Indian stock exchanges

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Elder Pharmaceuticals was listed on the Bombay Stock Exchange and the National Stock Exchange of India.

• 1989

  Elder Pharmaceuticals is founded

  [1]Elder Pharmaceuticalsen.wikipedia.org

  Jagdish Saxena founded Elder Pharmaceuticals in Mumbai after the pharmaceutical division of his former employer shut down. The company established its first manufacturing plant at Nerul.

Elder Pharmaceuticals positioned itself as an Indian branded-formulations and healthcare manufacturing company, spanning prescription medicines, medical devices, supplements, and selected consumer-health categories.

• Pharmaceuticals

  Prescription pharmaceutical formulations

  Elder’s core business involved the manufacture and marketing of branded prescription medicines for the Indian and Nepalese markets. The company worked across multiple dosage formats and maintained a portfolio-oriented model rather than relying on a single therapeutic product. Specific brand-level information is not sufficiently documented in the supplied material.

• Pharmaceutical manufacturing

  Solid and liquid dosage forms

  The company manufactured tablets, capsules, and syrups, supported by a broader production network in India and Nepal. These formats represented standard delivery forms for its prescription and healthcare portfolio.

• Pharmaceutical manufacturing

  Injectables and topical products

  Elder’s production capabilities included injectable medicines as well as topical creams and ointments. These formats expanded its manufacturing scope beyond oral solid and liquid products.

• Medical devices

  Surgical and medical devices

  Alongside medicines, Elder manufactured and marketed surgical products and medical devices. The supplied sources do not identify the individual device families or their clinical applications.

• Consumer health · 2010

  Nutritional supplements

  Elder expanded into nutritional supplements, including through its 2010 acquisition of NeutraHealth in the United Kingdom. The move gave the company a platform in the supplements and broader consumer-health market.

• Consumer health

  Nicotine-replacement products

  The company pursued an entry into the nicotine-replacement segment. Available material confirms the strategic foray but does not provide enough information to identify specific products or their commercial performance.

• Consumer health and personal care · 2006

  Skin-care products

  Elder explored skin-care products, including a reported agreement with Shahnaz Husain to launch four products during the 2006–07 period. Detailed product names and subsequent availability are not established in the supplied sources.

• 2006Shahnaz Husain skin-care partnership

  India

  Elder Pharma reportedly entered an agreement with Shahnaz Husain to launch four skin-care products during the 2006–07 period, extending the company into branded personal care.

  Outcome. The supplied material does not document the products’ long-term market performance or continuation.

  Source
• Rural-market expansion through Elvista

  India

  Elder established Elvista as a division dedicated to reaching rural markets, reflecting an effort to broaden distribution beyond established urban pharmaceutical channels.

  Outcome. No reliable outcome data is provided in the supplied references.

  Source

• 2016

  Delisting following non-complianceStrategy

  Background

  Elder’s financial and corporate difficulties continued after the sale of its branded domestic formulations business.

  Action taken

  The company was delisted from the Bombay Stock Exchange and National Stock Exchange because of non-compliance.

  Aftermath

  The delisting reduced the company’s access to public capital markets before its liquidation in 2017.

  Source

• 2013

  Sell branded domestic formulations business to Torrent PharmaceuticalsM&A

  Background

  Elder faced debt pressure and agreed to transfer a major operating segment covering branded formulations in India and Nepal.

  Action taken

  Torrent Pharmaceuticals signed a definitive agreement to acquire the business for ₹2,000 crore.

  Aftermath

  The sale did not resolve Elder’s broader debt crisis. The company was later delisted and entered liquidation.

  Transaction value. ₹2,000 crore (2013)

  Source

• 2010

  Acquire NeutraHealthM&A

  Background

  Elder sought to expand beyond prescription pharmaceuticals into supplements and consumer health.

  Action taken

  The company acquired the UK-based supplements business NeutraHealth for £12.2 million.

  Aftermath

  The acquisition broadened Elder’s international and consumer-health exposure, although later financial difficulties affected the group.

  Acquisition price. £12.2 million (2010)

  Source

1. 1Elder Pharmaceuticalsen.wikipedia.org